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We conducted a case–control study to analyse the association of psoriasis of recent onset with smoking habits,
body mass index (BMI) and stressful life events. Cases (n¼ 560; median age 38) were patients with a ﬁrst diagnosis
of psoriasis and a history of skin manifestations of no longer than two years after the reported disease onset.
Patients with a new diagnosis of skin diseases other than psoriasis (n¼ 690; median age 36) were selected as
controls. The risk of psoriasis was higher in ex- and current smokers than in never-smokers, the relative risk
estimates (OR) being 1.9 for ex-smokers and 1.7 for smokers. Smoking was strongly associated with pustular
lesions (32 patients, OR¼ 5.3 for smokers). The frequency of psoriasis varied signiﬁcantly in relation to a
family history of psoriasis in ﬁrst degree relatives, BMI (OR¼ 1.6 and 1.9 for over weighted, BMI 26–29, and obese,
BMI X 30, respectively) and stressful life event score (compared to the lower index quartile, the OR being 2.2 for
index values X115). Risk estimates, when taking into consideration the combined effect of these factors with
smoking habits, were consistent with a multiplicative model of risk combination with no signiﬁcant statistical
interaction.
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It is widely accepted that genetic–environmental interaction,
i.e., multifactorial heredity, plays a role in the development
of psoriasis. Although the genetic influence on psoriasis is
well established, the role of environmental factors is less
precisely defined. Smoking habits, alcohol consumption,
diet, body mass index (BMI), stressful life events, and in-
fections have been repeatedly considered as potentially
important causative factors (Naldi, 2004). Risk estimates
for these potentially modifiable factors are scanty. Such
estimates as well as the analysis of the combined effect of
exposure variables and the assessment of variations ac-
cording to specific clinical subtypes are important pieces of
evidence that may have both a theoretical value and im-
portant practical implication for the management of psoria-
sis and its disability prevention. We present a case–control
study involving newly diagnosed cases of psoriasis and
controls with newly diagnosed dermatological conditions
other than psoriasis. The aim of the study was to analyze
smoking habits and other commonly considered factors
associated with the development of psoriasis, to explore the
existence of variations in selected subgroups, and to eval-
uate the interaction between smoking and other document-
ed risk factors.
Results
The distribution of cases and controls according to
age, sex, marital status, family history of psoriasis in
first-degree relatives, alcohol consumption, BMI, and life
events index is presented in Table I. Thirty-four percent of
cases reported onset before age 30. No difference was
observed between cases and controls for gender, marital
status, or drinking habits. The risk of psoriasis was greater
in those reporting a family history of psoriasis in
first-degree relatives, the adjusted OR being 5.4 (95%
Abbreviations: BMI, body mass index; CI, confidence interval; DC,
dendritic cells; OR, odds ratio; TNF, tumor necrosis factor
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confidence interval (CI), 3.7–7.8). The mean number of
siblings was similar in cases and controls, 2.5 (standard
error¼ 0.12) in cases and 2.2 (standard error¼0.09) in
controls. The risk of psoriasis was directly related to BMI;
the OR was 1.6 (95% CI, 1.1–2.1) for BMI 26–29 corre-
sponding to overweight subjects, and 1.9 (95% CI, 1.2–
2.8) for BMI greater than 29, corresponding to obese peo-
ple. An association also emerged between psoriasis and
stressful life events in the year preceding the diagnosis.
The life events index is presented according to the quartile
distribution in the control group. The trend in risk was
significant (w2¼10.76, p¼ 0.001) but when males and
Table I. Distribution of 560 cases of psoriasis and 690 controls and OR estimates according to age, sex, marital status, family
history of psoriasis in ﬁrst-degree relatives, alcohol consumption, BMI, and life events index (Italy, 1988–1997)
Cases Controls
ORa (95% CI)Nd Percent Nd Percent
Age (y)
o30 188 33.6 236 34.2 1b
30–45 166 29.6 222 32.2 0.7 (0.5–1.1)
X46 206 36.8 232 33.6 0.7 (0.5–1.1)
w2 for trend is NS
Sex
Males 318 56.8 345 50.0 1b
Females 242 43.2 345 50.0 0.9 (0.7–1.2)
Marital status
Ever married 340 60.7 421 61.0 1b
Never married 220 39.3 269 39.0 1.1 (0.8–1.6)
Family history of psoriasis in first-degree relatives
No 407 72.8 643 93.5 1b
Yes 152 27.2 45 6.5 5.4 (3.7–7.8)
Never drinkers 127 22.7 185 26.8 1b
Former drinkers 15 2.7 20 2.9 0.7 (0.3–1.6)
Drinkers, drinks per day
o2 183 33.6 266 39.7 0.9 (0.7–1.3)
2–4 167 30.7 164 24.5 1.2 (0.9–1.8)
X5 67 12.3 55 8.2 1.4 (0.8–2.2)
w2 for trend is NS
BMI
o26 325 59.1 483 70.5 1b
26–29 154 28.0 145 21.2 1.6 (1.1–2.1)
X30 71 12.9 57 8.3 1.9 (1.2–2.8)
w2 for trend 11.8 p¼0.001
Life events indexc
o16 39 12.9 74 25.2 1b
16–57 89 29.4 74 25.2 1.6 (1.0–2.5)
58–114 70 23.1 73 24.8 2.2 (1.4–3.4)
X115 105 34.7 73 24.8 2.2 (1.4–3.4)
w2 for trend 10.76 p¼0.001
aMultiple logistic regression estimates, including terms for sex, age, marital status, hospitalization, education level, BMI, smoking, and alcohol habits.
bReference category.
cInformation was collected from 1992 (368 cases and 360 controls).
dSum of data may not equal the total because of missing values.
BMI, body mass index; OR, odds ratio; CI, confidence interval; NS, not significant.
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females were considered separately, the trend in risk was
evident for women only (data not presented).
Table II shows the distribution of cases and controls
according to smoking habits for the whole sample and
in gender strata. Overall, the OR for psoriasis was higher
in former and current smokers. The data, however, sug-
gested some gender differences. Male ex-smokers were
at an increased risk of psoriasis; the adjusted OR for men
being 2.1 (95% CI 1.3–3.5) whereas for women it was
1.2 (95% CI 0.6–2.2). For current smokers, the overall risk
was 1.7 (95% CI 1.1–3.0). The risk was higher in women
than men for whom the risk estimates seemed to corre-
spond to no effect at all. When the type of cigarettes was
considered categorized into four levels (very low, low, me-
dium, and high tar concentration), no marked differences
emerged; about 30% of current smokers usually smoked
very low or low tar cigarettes, 63% medium tar cigarettes,
and 4% high tar cigarettes, both in cases and controls
(data not shown). Smoking consumption was also con-
sidered in terms of pack years, calculated by multiplying
the number of packs of cigarettes smoked per day by the
number of years the person had smoked. The median
number of pack years was 11.8 in ex-smokers and 10.4 in
current smokers (this difference was not significant). Cigars
and pipe smoking accounted for only a minority of smoking
habits in our population. Taking these into account did not
materially change our risk estimates for smoking (data not
shown).
Table III considers the combined effect of smoking and,
in turn, family history of psoriasis among first-degree rela-
tives, alcohol consumption, BMI, and life events index. The
risk increased about 2-fold in smokers and drinkers as
compared with non-smokers non-drinkers, and about 9-fold
when smokers having a history of psoriasis in first-degree
relatives were compared with non-smokers with no family
history of psoriasis in first-degree relatives. The risk also
increased in smokers with a higher BMI, and in smokers
with a higher stressful life event index. The OR was around 3
for smokers with a BMIX30 and around 5 for smokers with
a life event indexX89 (30 and 89 being the approximate
tertiles of the life event index in the control group). These
results are in agreement with a multiplicative model for risk
combination between smoking habits and the other risk
factors analyzed.
Table IV presents OR estimates for smoking habits, BMI,
and life events index according to the clinical variety of pso-
riasis. A particularly strong association was confirmed be-
tween smoking and pustular psoriasis, OR¼ 5.3 (2.1–13.0).
Discussion
This study confirms that smoking, BMI, and stressful life
events are independently correlated with psoriasis, and that
their risks combine according to a multiplicative model
without evidence for statistical interaction. Our study high-
Table II. Distribution of 550 cases of psoriasis and 690 controls according to gender and smoking habits (Italy, 1988–1997)








(345) N (%) Males Females Combined
Never smokers 81 (25.6) 120 (34.8) 122 (50.4) 220 (63.8) 1b 1b 1b
Former smokers 83 (26.2) 57 (16.5) 20 (8.3) 34 (9.9) 2.1 (1.3–3.5) 1.2 (0.6–2.2) 1.9 (1.3–2.7)
Smokers, cigarettes per day
o1–10 46 (14.5) 56 (16.2) 53 (21.9) 52 (15.1) 1.3 (0.7–2.1) 2.1 (1.3–3.5) 1.6 (1.2–2.2)
11–20 72 (22.7) 77 (22.3) 42 (17.4) 36 (10.4) 1.2 (0.8–2.5) 2.3 (1.3–4.0) 1.7 (1.1–2.5)
X21 35 (11.0) 35 (10.1) 5 (2.1) 3 (0.9) 1.4 (0.8–2.0) 2.3 (0.4–14.2) 1.7 (1.0–3.2)
w2 for trend 11.4 po0.001
Duration of smoking habits (y)c
p5 33 (22.1) 30 (18.1) 23 (24.7) 20 (22.2) 1.4 (0.7–2.7) 1.8 (0.8–3.9) 1.6 (0.9–2.6)
6–14 33 (22.2) 34 (20.5) 28 (30.1) 22 (24.4) 1.4 (0.7–2.5) 2.8 (1.4–5.7) 1.9 (1.2–3.0)
X15 83 (55.7) 102 (61.5) 42 (45.2) 48 (53.3) 1.1 (0.6–1.7) 1.5 (0.9–2.6) 1.3 (0.9–1.8)
w2 for trend 5.67 p¼0.017
Exposure to passive smokingd
No 57 (27.5) 48 (24.6) 35 (22.2) 45 (27.6) 1b 1b 1b
Yes 150 (72.5) 147 (75.4) 123 (77.9) 118 (72.4) 1.0 (0.6–1.7) 1.4 (0.7–2.5) 1.6 (0.8–3.1)




dInformation was collected from 1992 (368 cases and 360 controls).
OR, odds ratio; CI, confidence interval.
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lights a relationship between smoking and psoriasis, show-
ing some gender difference and documenting a strong as-
sociation between smoking and pustular psoriasis.
Some limitations within our study design should be con-
sidered. Our cases were patients diagnosed for the first
time in their lives as suffering from psoriasis with a history of
skin manifestations no longer than 2 y. Our aim was to re-
strict the assessment to recently developed cases. In Italy,
specialist consultation is offered by the National Health
Service at the request of the primary care physician and it is
usual practice to refer all but the most trivial dermatology
cases. We took into account the first diagnosis of psoriasis
without any reference to disease severity. It is possible that
the risk factors we analyzed were correlated with disease
severity rather than mere disease occurrence. Unfortunate-
ly, we are unable to assess this relationship in our study. We
limited the entry criteria to subjects aged 16 y or older. As a
consequence, our data cannot be generalized to psoriasis
with an earlier onset where other factors may play an et-
iologic role. The choice of dermatological controls was
mainly dictated by the need to control reasons leading to
specialist consultation. We are aware that this may result in
overmatching (i.e., choosing controls too similar to cases
for the exposure variables). Our decision to use the date of
the first diagnosis by a specialist as the index date may be
questionable, the major problem being the inability to sep-
arate exposures to variables prior to clinical onset from ex-
posure to variables after clinical onset. With the exception
of psychological stress, however, all the factors we analy-
zed were long-lasting exposures usually preceding the on-
set of the disease by years. The retrospective nature of our
study is a more general limitation because of the potential
for recall and information bias. It is reassuring to note that
the prevalence of smokers in our control group was similar
to the estimates obtained in a study we recently conducted
on a representative sample of the Italian adult population
(Naldi et al, 2004). The study also documented an associ-
Table III. OR estimates for psoriasis according to combined
effect of smoking habits (never vs ever smokers) and, in turn,
family history in ﬁrst-degree relatives, alcohol consumption,
BMI, life events index (Italy, 1988–1997)
OR (95% CI)a
Never smokers Ever smokers
Family history of psoriasis in first-degree relatives
No 1b 1.7 (1.3–2.2)
Yes 5.2 (3.1–8.9) 9.2 (5.5–15.3)
Alcohol consumption
Never drinkers 1b 1.8 (1.1–2.8)
Drinkers 1.2 (0.8–1.7) 1.8 (1.3–2.6)
BMI
o26 1b 1.8 (1.4–2.5)
26–29 1.7 (1.1–2.7) 2.9 (1.9–4.2)
X30 2.5 (1.3–4.5) 3.0 (1.8–5.2)
Life events index
o30 1b 2.3 (1.2–4.5)
30–88 2.3 (1.2–4.4) 3.0 (1.6–5.7)
X89 2.1 (1.1–4.1) 4.9 (2.6–9.0)
aTest for interaction (diff in2 log likelihood model with and without
interaction terms); sex p¼ 0.416, drinking habits, p¼ 0.4; BMI, p¼ 0.8;
life events index, p¼ 0.7; family history of psoriasis¼ 0.1.
bReference category.
OR, odds ratio; BMI, body mass index; CI, confidence interval.
Table IV. OR estimates for smoking habits, BMI, and stressful life events index in selected clinical varieties of psoriasis
(Italy, 1988–1997)
Guttate (N¼98) Pustular (N¼ 32) Plaque (N¼ 415)
Cases OR (95% CI)c Cases OR (95% CI)c Cases OR (95% CI)c
Smoking habits
Never smokers 45 1a 7 1a 143 1a
Smokers 46 1.4 (0.9–2.2) 21 5.3 (2.1–13.0) 181 1.6 (1.2–2.1)
Ex-smokers 7 0.7 (0.3–1.6) 4 2.3 (0.8–10.1) 90 2.2 (1.5–3.2)
BMI
o26 65 1a 20 1a 231 1a
26–29 25 1.7 (1.0–3.0) 8 1.3 (0.5–3.3) 116 1.6 (1.2–2.2)
X30 5 0.8 (0.3–2.3) 4 1.6 (0.5–5.1) 61 2.2 (1.5–3.4)
Life events indexb
o30 12 1a 5 1a 44 1a
30–88 14 1.2 (0.5–2.7) 4 0.8 (0.2–3.0) 86 1.9 (1.2–3.1)
X89 30 2.4 (1.1–4.9) 5 1.1 (0.3–3.9) 95 2.2 (1.4–3.5)
aReference category.
bInformation was collected from 1992 (368 cases and 360 controls).
cMultiple logistic regression estimates, including terms for age and sex.
OR, odds ratio; BMI, body mass index; CI, confidence interval.
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ation between the prevalence of psoriasis and smoking,
providing further epidemiological support to our findings
(data on file). Recent Italian figures indicate that greater
proportions of men than women have given up smoking.
The association between previous smoker status and pso-
riasis in men may suggest that, as compared with the
controls, a greater proportion of male psoriatics gave up
smoking perhaps because of very early symptoms of the
disease. If selective quitting is implicated, then the risk for
current smoker status among men may be underestimated
by our study. The statistical power of most subgroup and
interaction analyses is inadequate. As a consequence, more
weight should be given to our overall results rather than to
any specific result in subgroups.
Previous studies have provided some evidence for the
association of psoriasis with smoking habits, BMI, and
stressful life events. Interestingly, a number of diseases that
are strongly linked with smoking in the general population,
including among others, Crohn’s disease (Lee et al, 1990),
lung cancer, and tumors of the upper airways (Olsen et al,
1992; Boffetta et al, 2001) are also associated with psoria-
sis. Obesity has been linked with psoriasis in studies of
prevalent cases (Vessey et al, 2000) and in a previous anal-
ysis of our dataset (Naldi et al, 1996). In spite of being fre-
quently reported as a trigger, there is limited and conflicting
evidence concerning the role of psychological stress in re-
lation to the onset or exacerbation of psoriasis (Gupta et al,
1987, 1989; Picardi et al, 2001, 2003). Our study has con-
firmed these previously reported associations and provides
evidence that stressful life events are linked to psoriasis
at its first diagnosis. Several tentative biological explana-
tions can be suggested for the associations we have doc-
umented. The following speculations are not meant to be
exhaustive; they rather hint at possible connections and
explanations that may be worthy of further research.
Smoke The effect of smoking is the sum of complex ac-
tions of various substances, including nicotine and carbon
monoxide, and is modulated by gender, genetic back-
ground, cigarette dose, and nicotine concentration.
Psoriasis is a T cell immune-mediated disease and nic-
otine alters a wide range of immunological functions, in-
cluding innate and adaptive immune responses (McAllister-
Sistilli et al, 1998; Sopori, 2002). But contrasting results,
according to the experimental model adopted, have been
provided.
Nicotine can modulate the functional capacity of dendri-
tic cells (DC) (Aicher et al, 2003; Nouri-Shirazi and Guinet,
2003). Using human and murine DC, which are professional
antigen-presenting cells (APC), it has been recently docu-
mented that nicotine can concentration-dependently induce
DC expression of costimulatory molecules (i.e., CD86,
CD40), MHC class II, and adhesion molecules (i.e., LFA-1,
CD54). Moreover, nicotine induced a significant increase in
the secretion of the proinflammatory T helper 1 cytokine
interleukin-12 by human DC. These effects were abrogated
by the nicotinic receptor antagonists a-bungarotoxin and
mecamylamine. The greater capacity of nicotine-stimulated
APC to induce T cell proliferation and cytokine secretion
was also documented in mixed lymphocyte reaction and
antigen-specific assays. Ovalbumin-stimulated T cells from
DO10.11 mice bearing the specific transgenic T cell recep-
tor were used (Aicher et al, 2003).
Other experiments involving chronic exposure of mice
and rats have showed that cigarette smoke affects T cell
responsiveness, which may account for the decreased Tcell
proliferative and T-dependent antibody responses in hu-
mans and animals exposed (Kalra et al, 2000). In LEW rats,
a decreased response to sheep red blood cells by antibody
plaque-forming cells (AFC) was also observed after in-
tracerebroventricular administration of relatively small con-
centrations of nicotine (28 mg per day per kg body weight),
which when given peripherally, did not affect the AFC re-
sponse (Sopori et al, 1998). These results support the hy-
pothesis that nicotine alters immune responses by directly
interacting with T cells and human and/or murine DC, as
well as indirectly through brain–immune interactions. In ad-
dition, nicotinic cholinergic receptors have been demon-
strated on keratinocytes stimulating calcium influx and
accelerating cell differentiation (Grando et al, 1996). Con-
stant stimulation of these receptors may control keratin-
ocyte adhesion and upward migration in the epidermis.
As we have already mentioned, psoriasis has been as-
sociated with Crohn’s disease and less consistently with
ulcerative colitis (Yates et al, 1982; Lee et al, 1990; Najarian
and Gottlieb, 2003). A large body of evidence indicates that
smoking triggers Crohn’s disease and influences disease
progression (Cosnes et al, 2001, 2004). As observed in
psoriasis, these effects are modulated significantly by gen-
der, with women being at a greater disadvantage than
men. The possibility of a common susceptibility gene, i.e.,
CARD15, in Crohn’s disease and psoriatic arthritis, was re-
cently suggested (Rahman et al, 2003) but not confirmed
(Giardina et al, 2004). Differing from Crohn’s disease, former
but not current smokers appear to be at increased risk for
ulcerative colitis. It has been postulated that the withdrawal
of the immunosuppressive effect of smoking triggers the
disease onset in a genetically susceptible individual or sim-
ply unmasks its symptoms (Abraham et al, 2003). Such
a hypothesis may be relevant to explain the association
we have documented between former smoking status and
psoriasis in men.
BMI BMI is a complex variable that correlates fairly well
with the degree of adiposity, and is affected by both genetic
and environmental factors, e.g., caloric intake (Bjorntorp,
1997; Rosenbaum et al, 1997). BMI, in turn, appears to af-
fect several biological variables including immunity (Tanaka
et al, 1993, 2001). It has been documented that circulatory
levels of tumor necrosis factor (TNF)-a, soluble TNF-a re-
ceptors, and in vitro TNF-a production are significantly in-
creased in obese subjects as compared with non-obese
subjects. In obese subjects, there is a significant positive
correlation between serum levels of TNF-a and waist–hip
ratio, serum levels of soluble TNF-a receptor 1 and body
weight, and soluble TNF-a receptor 2 and BMI. The T cell
responses and previously reduced T cell subsets increase
significantly following weight reduction (Tanaka et al, 2001).
It has been documented that fasting may improve at least
temporarily inflammatory conditions including psoriasis
(Lithell et al, 1983; Kragh-Kjeldsen et al, 1991). Recently, a
link has been established between obesity and a proin-
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flammatory state in the so-called metabolic syndrome
(Grundy et al, 2004).
Stress There is some evidence to suggest that psycholog-
ical stress may modulate immune functions in humans
and experimental animals, depending on the nature of the
stressor and the immune variable under consideration (Miller
et al, 1998). Interestingly, it has been documented that stress-
induced anxiety is related to a T helper 1-like response (Maes
et al, 1998). Based on experiments where a psychological
stress was applied before immunization, it has been pro-
posed that stress exerts an adjuvant effect on DC by pro-
moting enhanced migration to lymph nodes and resulting in
increased antigen-specific T cell responses. Such an effect
appears to be modulated by release of norepinephrine by
sympathetic nerve ends (Saint-Mezard et al, 2003).
Conclusions Our data indicate that chronic exposure to
selected environmental factors, i.e., smoking, and more
acute triggers, i.e., psychological stress, may influence the
development of psoriasis and affect its clinical expression.
The impact of the factors we have analyzed on the causa-
tion of psoriasis is far from negligible from a public health
point of view. In terms of population attributable risk (Bruzzi
et al, 1985) tobacco smoking accounted for 26% of all the
psoriasis cases, family history of psoriasis in first-degree
relatives accounted for 22%, and BMI accounted for 16%.
When the combined effect of tobacco and BMI was con-
sidered, it accounted for 48% of all the cases in this pop-
ulation and 42% in people without a family history of
psoriasis. Similar considerations can also apply to stressful
life events.
The effect of environmental factors on the extension,
distribution (e.g., acral lesions), clinical variety, and re-
sponse to treatment of psoriasis should be further evaluated
in prospective studies.
Subjects and Methods
The general design of this study has been previously described
(Naldi et al, 1992, 1996, 1999). Briefly, between January 1988 and
December 1997, trained interviewers identified and interviewed
cases and controls using a standard questionnaire. The study was
conducted in three separate periods (1988–1991, 1992–1993,
1994–1997). It was our aim to recruit about 200 cases, during each
study period, with a similar number of controls. Analyses were
conducted at the end of each study period and more focused
hypotheses were formulated for the next study phase. These hy-
potheses involved amending the questionnaire and adding in new
items (in particular, life events index and passive smoking were
added in 1992). The study involved a total of 20 dermatologic
centers from different Italian regions (14 centers from northern
Italy). The results of the three phases of the study were compa-
rable, and no significant differences between participating centers
were observed. The study has been approved by the medical eth-
ical committee of the Bergamo General Hospital. The study was
conducted according to the Declaration of Helsinki Principles.
Participants gave their written informed consent.
Only subjects aged 16 y or older were eligible. Entry criteria for
cases were as follows: a first ever diagnosis of psoriasis made by a
dermatologist and a history of skin manifestations up to 2 y after
the reported disease onset. The onset was considered as the date
an individual first became aware of the clinical manifestations at-
tributable to psoriasis. The definition of onset was established by a
thorough enquiry into the timing of relevant signs and symptoms.
All eligible patients who were seen consecutively during the study
period were invited to participate.
A total of 560 cases (318 males, 242 females, median age 38 y)
and 690 controls (345 males, 345 females, median age 36 y) were
included. The psoriasis cases were classified as: psoriasis vulgaris
(415, 74.1%), guttate (98, 17.5%), pustular, i.e., plaque psoriasis
associated with pustular lesions and generalized pustular psoriasis
(32, 5.7%), and other varieties including flexural and erythrodermic
psoriasis (15, 2.7%). Controls were patients attending the same
out-patient centers as the cases, with a first diagnosis of a der-
matological condition other than psoriasis. Diagnoses in the con-
trol group included eczema (25%), skin cancer (16%), urticaria
(14%), skin infections (13%), pityriasis rosea (10%), acne (8%),
reported changes in melanocytic nevi (8%), rosacea (2%), an-
giomatous lesions (2%), and a variety of other skin diseases (2%).
Less than 3% of cases and controls refused to be interviewed.
Information was collected on sociodemographic factors, smok-
ing habits (daily consumption of cigarettes, cigar, and pipe), alco-
hol, coffee, and tea consumption, consumption of selected dietary
factors, family history of psoriasis in first-degree relatives (i.e.,
parents and siblings), history of stressful life events, and thorough
medical history. Anthropometric measures including height and
weight were also obtained.
A period of abstinence of 1 y before the date of diagnosis was
required for patients to be classified as ex-smokers or ex-drinkers.
An Italian version of the Holmes and Rahe Social Readjustment
Rating Scale was used to assess stressful life events during the
year before the diagnosis. The scale included 47 items, each pro-
viding a score proportional to the associated stress, e.g., partner
death (score 100), pregnancy (score 40), job troubles (score 23),
small law violations (score 11, the smallest score in the scale). Total
sum scores on the scale were used for the analysis.
Data analysis For each factor, we calculated the OR of psoriasis as
estimates of relative risks and its corresponding 95% CI. To account
simultaneously for the effects of age, sex, calendar year, and other
selected covariates, unconditional multiple logistic regression with
maximum likelihood fitting was used (Breslow and Day, 1980).
Attributable risks were calculated by means of the method de-
scribed by Bruzzi et al (1985).
The study was partly supported by grants from the following drug
companies: Janssen-Cilag, Roche, Schering, Boehringer Ingelheim,
Glaxo-Wellcome, Novartis. The contribution of the Italian League
against Cancer is also gratefully acknowledged. We wish to thank Le-
igh Martin for editorial assistance and the dermatologists in the par-
ticipating centers for making this study possible. We are grateful to
Lucienne Chatenoud for her helpful suggestions.
Supplementary Material
The following material is available from http://www.blackwellpublishing.
com/products/journals/suppmat/JID/JID23681/JID23681sm.htm
Supplemental Text: Questionnaire employed to collect data.
DOI: 10.1111/j.0022-202X.2005.23681.x
Manuscript received September 1, 2004; revised December 16, 2004;
accepted for publication December 20, 2004
Address correspondence to: Dr Luigi Naldi, Centro Studi GISED, Os-
pedali Riuniti, L.go Barozzi 1, 24100 Bergamo, Italy. Email: luigi.naldi@
gised.it
References
Abraham N, Selby W, Lazarus R, Solomon M: Is smoking an indirect risk factor for
the development of ulcerative colitis? An age- and sex-matched case–
control study. J Gastroenterol Hepatol 18:139–146, 2003
66 NALDI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Aicher A, Heeschen C, Mohaupt M, Cooke JP, Zeiher AM, Dimmeler S: Nicotine
strongly activates dendritic cell-mediated adaptive immunity: Potential
role for progression of atherosclerotic lesions. Circulation 1007:e9007–
e9007, 2003
Bjorntorp P: Obesity. Lancet 350:423–426, 1997
Boffetta P, Gridley G, Lindelof B: Cancer risk in a population-based cohort hos-
pitalized for psoriasis in Sweden. J Invest Dermatol 117:1531–1537, 2001
Breslow NE, Day NE: Statistical Methods in Cancer Research. Vol. 1. The Anal-
ysis of Case–Control Studies. No 32. Lyon, France: IARC Sci Publ., 1980
Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C: Estimating the population
attributable risk for multiple factors using case–control data. Am J
Epidemiol 122:904–914, 1985
Cosnes J, Beaugerie L, Carbonnel F, Genere JP: Smoking cessation and the
course of Crohn’s disease: An intervention study. Gastroenterology 120:
1093–1099, 2001
Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP: Gender differ-
ences in the response of colitis to smoking. Clin Gastroenterol Hepatol
2:41–48, 2004
Giardina E, Novelli G, Costanzo A, et al: Psoriatic arthritis and CARD15 gene
polymorphisms: No evidence for association in the Italian population.
J Invest Dermatol 122:1106–1107, 2004
Grando SA, Horton RM, Mauro TM, Kist DA, Lee TX, Dahl MV: Activation of
keratinocyte nicotinic cholinergic receptors stimulates calcium influx and
enhances cell differentation. J Invest Dermatol 107:412–418, 1996
Grundy SM, Brewer B, Cleeman JI, et al: Definition of metabolic syndrome. Re-
port of the National Heart, Lung, and Blood Institute/American Heart
Association Conference on Scientific Issues Related to Definition.
Circulation 109:433–438, 2004
Gupta MA, Gupta AK, Haberman HF: Psoriasis and psychiatry: An update. Gen
Hosp Psychiatry 9:157–166, 1987
Gupta MA, Gupta AK, Kirkby S, Schork NJ, Gorr SK, Ellis CN, Voorhees JJ:
A psychocutaneous profile of psoriasis patients who are stress reactors:
A study of 127 patients. Gen Hosp Psychiatry 11:166–173, 1989
Kalra R, Singh SP, Savage SM, Finch GL, Sopori ML: Effects of cigarette smoke
on immune response: Chronic exposure to cigarette smoke impairs an-
tigen-mediated signalling in T cells and depletes IP3-sensitive Ca(2þ )
stores. J Pharmacol Exp Ther 293:166–171, 2000
Kragh-Kjeldsen J, Haugen M, Borchgrevinck CF, et al: Controlled trial of fasting and
one-year vegetarian diet in rheumatoid arthritis. Lancet 338:899–902, 1991
Lee FI, Bellary SV, Francis C: Increased occurrence of psoriasis in patients with
Crohn’s disease and their relatives. Am J Gastroenterol 85:962–963, 1990
Lithell H, Bruce A, Gustafsson IB, et al: A fasting and vegetarian diet treatment
trial on chronic inflammatory disorders. Effects on clinical condition and
serum levels of neutrophil-derived granule proteins. Acta Derm Venereol
(Stockh) 63:397–403, 1983
Maes M, Song C, Lin A, et al: The effects of psychological stress on humans:
Increased production of pro-inflammatory cytokines and a Th1-like re-
sponse in stress-induced anxiety. Cytokine 10:313–318, 1998
McAllister-Sistilli CG, Caggiula AR, Knopf Rose CA, Miller AL, Donny EC: The
effects of nicotine on the immune system. Psychoneuroendocrinology
23:175–187, 1998
Miller AH: Neuroendocrine and immune system interactions in stress and de-
pression. Psychiatr Clin North Am 21:443–463, 1998
Najarian DJ, Gottlieb AB: Associations between psoriasis and Crohn’s disease.
J Am Acad Dermatol 48:805–821, 2003
Naldi L: Epidemiology of psoriasis. Curr Drug Targets, Inflammation Allergy
3:121–128, 2004
Naldi L, Colombo P, Placchesi EB, et al: Study design and preliminary results from
the pilot phase of the PraKtis study: Self-reported diagnoses of selected
skin diseases in a representative sample of the Italian population. Der-
matology 208:38–42, 2004
Naldi L, Parazzini F, Brevi A, et al: Family history, smoking habits, alcohol con-
sumption and risk of psoriasis. Br J Dermatol 127:212–217, 1992
Naldi L, Parazzini F, Peli L, et al: Dietary factors and the risk of psoriasis. Results
of an Italian Case–Control Study. Br J Dermatol 134:101–106, 1996
Naldi L, Peli L, Parazzini F, et al: Association of early-stage psoriasis with smoking
and male alcohol consumption. Evidence from an Italian Case–Control
Study. Arch Dermatol 135:1479–1484, 1999
Nouri-Shirazi M, Guinet E: Evidence for the immunosuppressive role of nicotine
on human dendritic cell functions. Immunology 109:329–330, 2003
Olsen JH, Mller H, Frentz G: Malignant tumors in patients with psoriasis. J Am
Acad Dermatol 27:716–722, 1992
Picardi A, Abeni D: Stressful life events and skin diseases: Disentangling
evidence from myth. Psychother Psychosom 70:118–136, 2001
Picardi A, Pasquini P, Cattaruzza MS, et al: Only limited support for a role of
psychosomatic factors in psoriasis. Results from a case–control study.
J Psychosom Res 55:189–196, 2003
Rahman P, Bartlett S, Siannis F, et al: CARD15: A pleiotropic autoimmune gene
that confers susceptibility to psoriatic arthritis. Am J Hum Genet 73:
677–681, 2003
Rosenbaum M, Leibel R, Hirsch J: Obesity. N Engl J Med 337:396–407, 1997
Saint-Mezard P, Chavagnac C, Bosset S, et al: Psychological stress exerts an
adjuvant effect on skin dendritic cell functions in vivo. J Immunol 171:
4073–4080, 2003
Sopori M: Effects of cigarette smoking on the immune system. Nat Rev Immunol
2:372–377, 2002
Sopori ML, Kozak W, Savage SM, et al: Effect of nicotine on the immune system:
Possible regulation of immune responses by central and peripheral
mechanisms. Psychoneuroendocrinology 23:189–204, 1998
Tanaka S, Inoue S, Isoda F, et al: Impaired immunity in obesity: Suppressed but
reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord
17:631–636, 1993
Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T: T lymphopaenia in
relation to body mass index and TNF-aplha in human obesity: Adequate
weight reduction can be corrective. Clin Endocrinol (Oxford) 54:347–354,
2001
Vessey MP, Painter R, Powell J: Skin disorders in relation to oral contraception
and other factors, including age, social class, smoking and body mass
index. Findings in a large cohort study. Br J Dermatol 143:815–820, 2000
Yates VM, Watkinson G, Kelman A: Further evidence for an association between
psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol 106:
323–330, 1982
RISK FACTORS FOR PSORIASIS 67125 : 1 JULY 2005
